Enclomiphene Citrate vs Jatenzo: Cost and Access Head-to-Head

Mechanism of Action: Two Opposite Strategies

Enclomiphene citrate and Jatenzo represent fundamentally different pharmacologic approaches to raising serum testosterone. One stimulates endogenous production. The other replaces it entirely.

Enclomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, increasing gonadotropin (LH and FSH) secretion [1]. This drives the testes to produce more testosterone without shutting down the hypothalamic-pituitary-gonadal (HPG) axis. Kim et al. demonstrated in a 2016 study (N=48) that enclomiphene restored serum testosterone from a mean baseline of 228 ng/dL to 451 ng/dL at 3 months while maintaining sperm concentration above baseline values 1.

Jatenzo delivers exogenous testosterone undecanoate in a lipid-based oral capsule absorbed through the intestinal lymphatic system. The Swerdloff et al. registration trial (N=166) found that 87% of patients achieved eugonadal serum T levels (between 300, 1 to 100 ng/dL) at 3 months on the adjusted dose [2]. Because it supplies exogenous testosterone, Jatenzo suppresses LH and FSH through negative feedback, effectively halting spermatogenesis in most men within 8 to 12 weeks of initiation.

This mechanistic divergence creates the central clinical trade-off: fertility preservation versus reliable exogenous replacement.

Monthly Cost Breakdown

The price gap between these two drugs is substantial, though insurance and copay programs narrow it for some patients.

Enclomiphene citrate is available exclusively through compounding pharmacies in the United States, since the branded product (Androxal) never received FDA approval despite completing Phase III trials. Compounded enclomiphene typically costs $30, $120 per month depending on the pharmacy, dose (12.5 to 50 mg/day), and whether the prescription is filled through a telehealth platform or local compounder. Cash-pay pricing dominates because insurance plans rarely reimburse compounded SERMs for male hypogonadism.

Jatenzo carries a wholesale acquisition cost (WAC) of approximately $580 per month for the 158 mg twice-daily starting dose. Retail pharmacy pricing ranges from $500, $900/month without insurance. The manufacturer (Clarus Therapeutics, acquired by Halozyme in 2023) offers a copay assistance card reducing out-of-pocket costs to $0, $75/month for commercially insured patients meeting eligibility criteria 3.

For uninsured patients paying cash, enclomiphene costs roughly 75 to 90% less than Jatenzo per month. For commercially insured patients with Jatenzo formulary coverage and copay card activation, the monthly out-of-pocket difference shrinks to near parity or even favors Jatenzo at $0, $75.

Insurance Coverage and Prior Authorization

Jatenzo holds FDA approval (March 2019) for adult males with conditions associated with a deficiency or absence of endogenous testosterone. This regulatory status grants it formulary placement on most major commercial plans, though typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) positioning. Prior authorization requirements are standard: most payers demand two morning serum total testosterone values below 300 ng/dL plus a documented etiology 4.

Enclomiphene lacks FDA approval for any indication. Insurers treat compounded enclomiphene as a non-covered pharmacy benefit in the vast majority of plans. Some patients have obtained partial coverage through medical benefit exceptions when prescribed for off-label use in secondary hypogonadism with documented fertility concerns, but this remains uncommon.

Medicare Part D does not cover compounded medications. Jatenzo is listed on some Medicare Part D formularies but often requires step therapy (failure of topical testosterone first) and carries a coverage gap ("donut hole") liability of 25% coinsurance, putting monthly costs at $125, $225 during the gap phase.

The Endocrine Society's 2018 guidelines recommend testosterone therapy for symptomatic men with unequivocally low testosterone but do not specifically endorse enclomiphene, noting that SERMs for male hypogonadism remain off-label 5.

Clinical Efficacy: What the Trials Show

No direct head-to-head trial comparing enclomiphene to Jatenzo exists. Comparisons must be drawn across separate study populations with different designs.

Kim et al. (BJU International, 2016) enrolled 48 men with secondary hypogonadism (baseline T 228 ± 54 ng/dL) and treated them with enclomiphene 25 mg daily for 3 months 1. Mean testosterone rose to 451 ng/dL (a 98% increase from baseline). LH increased from 3.2 to 7.1 mIU/mL. Sperm concentration was maintained at or above baseline in all participants. The study was open-label and relatively small.

Swerdloff et al. (Journal of Clinical Endocrinology & Metabolism, 2020) enrolled 166 hypogonadal men in a dose-titration study of oral testosterone undecanoate 2. At the 3-month endpoint, 87% achieved serum T within the eugonadal range (300, 1 to 100 ng/dL). Mean Cavg was 489 ng/dL. The REMS (Risk Evaluation and Mitigation Strategy) program was required due to a signal of blood pressure elevation: systolic BP increased by a mean of 3 to 5 mmHg across dose groups.

Comparing these figures directly is imprecise. The populations differed (secondary vs. mixed hypogonadism), sample sizes differed by 3.5-fold, and endpoints were defined differently. What can be stated: both drugs raise testosterone into the normal range for most men within 3 months of initiation.

Fertility Preservation: The Deciding Factor for Many Men

For men aged 25, 40 who plan to conceive within the next 1 to 5 years, this comparison often resolves quickly. Enclomiphene preserves fertility. Jatenzo does not.

Exogenous testosterone (including Jatenzo) suppresses intratesticular testosterone concentrations by 90 to 95% within weeks of starting therapy, which arrests spermatogenesis 6. Recovery after discontinuation is variable: a meta-analysis by Liu et al. found median time to return of spermatogenesis was 3 to 6 months, but 10 to 15% of men experienced prolonged oligospermia beyond 12 months.

Enclomiphene, by stimulating the HPG axis rather than suppressing it, maintains or improves sperm parameters. The Kim et al. data showed stable sperm concentration at 3 months [1]. A separate retrospective analysis by Wiehle et al. (2014) found that enclomiphene 12.5 to 25 mg maintained sperm motility above 40% in 91% of treated men over 6 months 7.

The American Urological Association recommends against testosterone therapy for men desiring near-term fertility and suggests SERMs or hCG as alternatives 8. This guideline effectively steers fertility-minded patients toward enclomiphene (or clomiphene) and away from Jatenzo.

Access and Availability

Getting a prescription filled involves different pathways for each drug.

Jatenzo is available at any U.S. retail pharmacy with a REMS-certified dispensing process. Major chains (CVS, Walgreens, Rite Aid) stock it. The REMS requirement adds a step: prescribers must enroll in the Jatenzo REMS program and counsel patients on the blood pressure monitoring requirement (home BP checks for the first 6 months). This is a one-time provider enrollment, not a per-patient barrier.

Enclomiphene access requires a compounding pharmacy willing to compound the drug and a prescriber comfortable writing off-label prescriptions. Telehealth TRT clinics (including HealthRX) have become primary access points for enclomiphene, handling both the prescription and pharmacy coordination. State-level compounding regulations vary. Some states restrict patient access to out-of-state 503A compounding pharmacies, while 503B outsourcing facilities can ship across state lines under FDA oversight.

Supply consistency differs too. Jatenzo has experienced no significant shortages since launch. Compounded enclomiphene faced intermittent supply disruptions in 2023 to 2024 when the FDA issued warning letters to certain compounders regarding bulk drug substance sourcing, though availability has since stabilized.

Safety and Monitoring Differences

Both drugs require ongoing laboratory monitoring, but the surveillance protocols differ based on their mechanisms.

Jatenzo monitoring includes: serum total testosterone (trough, measured pre-morning dose) at 1 month and 3 months, then every 6 to 12 months; hematocrit every 3 to 6 months (polycythemia risk; 3.8% incidence in trials); fasting lipids annually (HDL suppression is modest with oral TU vs. injectable T); and home blood pressure monitoring per REMS requirements 2. PSA screening follows standard AUA guidelines for age.

Enclomiphene monitoring includes: serum total testosterone, LH, FSH, and estradiol at 4 to 6 weeks and 3 months; semen analysis if fertility is the indication; hematocrit (polycythemia risk is lower than exogenous T but not zero); and hepatic panel at baseline. Visual disturbances (a class effect of SERMs noted with clomiphene at rates of 1 to 2%) warrant prompt ophthalmologic referral, though enclomiphene's trans-isomer specificity appears to reduce this risk compared to racemic clomiphene 9.

Drug-drug interactions are minimal for both. Jatenzo absorption is fat-dependent (must be taken with meals containing at least 15 g of fat). Enclomiphene has no significant food interaction.

Who Should Choose Which Drug

The decision matrix breaks along three axes: fertility status, insurance coverage, and regulatory comfort.

Choose enclomiphene if: you want to preserve fertility or may want children in the future; you are comfortable with an off-label, non-FDA-approved medication; you prefer lower monthly costs regardless of insurance status; your hypogonadism is secondary (hypothalamic/pituitary origin) rather than primary testicular failure; or your baseline LH is low-normal (indicating the HPG axis can respond to stimulation).

Choose Jatenzo if: fertility is not a concern (vasectomy, completed family, or primary hypogonadism); you want an FDA-approved oral option with established REMS-supported safety monitoring; your insurance covers brand TRT and the copay card brings costs to $0, $75/month; you have primary hypogonadism where enclomiphene cannot work (damaged testes will not respond to increased LH); or you prefer a drug with Phase III registration-quality safety data.

Men with primary hypogonadism (elevated LH, low T) should not use enclomiphene. The drug requires functional Leydig cells to produce testosterone in response to gonadotropin stimulation. If the testes cannot respond, enclomiphene will raise LH further without raising T.

Switching Between Therapies

Transitioning from one drug to the other is clinically straightforward but requires attention to timing and monitoring.

Switching from Jatenzo to enclomiphene (common scenario: man on TRT who now wants fertility): discontinue Jatenzo, wait 2 to 4 weeks for exogenous testosterone to clear, check LH/FSH/total T to confirm HPG axis recovery has begun, then initiate enclomiphene 25 mg daily. Full HPG axis recovery may take 4 to 12 weeks. Some clinicians bridge with hCG (1,000, 1 to 500 IU three times weekly) during the washout to prevent a symptomatic testosterone trough.

Switching from enclomiphene to Jatenzo (common scenario: man who has completed family planning): enclomiphene can be discontinued without a washout period. Start Jatenzo 158 mg twice daily with food on the same day or next day. Check serum T at 1 month to confirm dose adequacy.

The Regulatory Future

Enclomiphene's FDA path has been uncertain since Repros Therapeutics (later Allergan) withdrew its New Drug Application in 2018 after receiving a Complete Response Letter. No sponsor currently holds an active NDA for enclomiphene citrate as of May 2026. The drug's continued availability depends entirely on the compounding pharmacy framework under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act 10.

If the FDA were to restrict enclomiphene citrate from the bulk drug substances list (as it has done with other hormonal compounds), access could narrow significantly. Patients currently using compounded enclomiphene should discuss contingency plans with their prescribing clinician, including hCG monotherapy or low-dose clomiphene as alternative fertility-preserving options.

Jatenzo's market position faces competitive pressure from generic injectable testosterone (cypionate and enanthate at $30, $60/month) and from newer oral testosterone formulations entering clinical development. Its patent estate provides exclusivity protection into 2031.

The Endocrine Society's next guideline revision (expected 2026 to 2027) may incorporate stronger language on SERMs for secondary hypogonadism given accumulating observational data, though formal randomized controlled trial evidence supporting enclomiphene over clomiphene specifically remains limited.